Collaborations

Trilaciclib CollaborationS
 

boehringer ingelheim logo

We have a co-promotion agreement with Boehringer Ingelheim for trilaciclib in small cell lung cancer in the United States and Puerto Rico. Click here to learn more about our partnership, and here for more information on trilaciclib.

simcere logo

We are collaborating with Simcere Pharmaceutical Group on development and commercialization of trilaciclib in Greater China. Click here to learn more about our agreement, and here for more information about trilaciclib.


Rintodestrant Collaborations
 

pfizer logo

We have a non-exclusive clinical supply agreement with Pfizer to provide Ibrance® (palbociclib) for our rintodestrant/palbociclib combination trial. Click here to learn more about rintodestrant, and here for information on ongoing clinical trials.


Lerociclib Collaborations
 

EQRx logo

We have an exclusive license agreement with EQRx for lerociclib in the United States, Europe, Japan and other territories. Click here to learn more about our agreement, and here for more information about lerociclib.

genor logo

We have an exclusive license agreement with Genor Biopharma for lerociclib in the Asia-Pacific region. Click here to learn more about our agreement, and here for more information about lerociclib.